ClinicalTrials.gg
RecruitingNCT04634357ARYA-2Updated Jul 6, 2026

ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma

A Phase 1/2 interventional study of ET140203 T Cells in Hepatoblastoma, Hepatocellular Carcinoma (HCC) and Liver Neoplasms, sponsored by Eureka Therapeutics Inc.. Recruiting at 4 sites in United States. Open to participants aged 1 Year to 21 Years. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Eureka Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
12
Allocation
Not applicable
Ages
1 Year to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Hepatoblastoma with a site in United States — 11 open to participants now, 25 under way, 1 of them phase 3. Hepatoblastoma · United States.

Planned enrollment
39th of 48
12 · median 23
Started
2022
with 3 others
Phase 1/2
6 of 54
3 open now
Primary completion
2027-12
later than 17 of 24 live
Registered
43rd of 54
by date

Among the 54 studies in Hepatoblastoma with a site in United States, this one is the 39th largest by planned enrollment of the 48 interventional ones that give a count, is one of 4 that started in 2022, is one of 6 in phase 1/2, reaches primary completion later than 17 of the 24 other live ones, and was the 43rd registered.

Hepatoblastoma

82 studies on the registry are indexed under Hepatoblastoma; 17 are open to participants now.

Browse Hepatoblastoma studies →

Open to participants now

11 of the 54 studies in Hepatoblastoma with a site in United States are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Hepatoblastoma studies recruiting now, 2 (13%) set no upper age limit and 13 (81%) stop at 75 or younger; 15 take children under 18; none take healthy volunteers.

This study: 1 Year to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Hepatoblastoma with a site in United States, or all of them as a file.
02

Study summary

Open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety/tolerability and determine the recommended Phase II Dose (RP2D) of ET140203 T-cells in pediatric subjects who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

Read the detailed description

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of intravenous (IV) administration of ET140203 T cells and determine the recommended Phase II dose (RP2D) of ET140203 T-cell therapy in pediatric subjects (age ≥ 1 year and ≤ 21 years) who are AFP-positive/HLA-A2-positive and have relapsed/refractory HB, HCN-NOS, or HCC.

A traditional dose escalation model (3+3 design) will be used to determine the RP2D, and once determined, the expansion phase will commence. A statistically relevant number of subjects will be treated at the RP2D in the expansion phase to adequately assess the therapeutic benefits and risks of ET140203 T-cell therapy. Tumor response assessments will be performed prior to 1st infusion (baseline) and at Months 1, 3, 6, 9, 12, 18, and 24. At each tumor response assessment visit, radiographic imaging will be performed and used for response evaluation. Serum AFP levels will also be measured at each tumor response assessment visit.

The active assessment period of the study will continue for 2 years. Subjects will be followed for assessment of treatment safety and overall survival during long-term follow-up (LTFU; Year 2-15).

03

Conditions studied

  • Hepatoblastoma
  • Hepatocellular Carcinoma (HCC)
  • Liver Neoplasms
  • Metastatic Liver Cancer
  • Liver Cancer
  • HEMNOS

Keywords

  • Relapsed/Refractory Hepatoblastoma (HB)
  • Pediatric
  • Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS)
  • Hepatocellular Carcinoma (HCC)
  • Liver Cancer
  • T-cell therapy
  • Metastatic Liver Cancer
  • Liver neoplasms
  • HEMNOS
04

Who can participate

Ages eligible
1 Year to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. confirmed HB, HCN-NOS, or HCC with serum AFP >100ng/mL at the time of screening and following the most recent .
  2. Disease recurrence after remission following initial standard-of care (SOC) treatment (i.e., relapse) or failure of response to SOC treatment (i.e., ).
  3. Age ≥ 1 year and ≤ 21 years.
  4. Molecular Human Leukocyte Antigen (HLA) class I allele typing that confirms subject carries at least one HLA-A2 allele.
  5. of > 4 months per the Investigator's opinion.
  6. Lansky or Performance Scale ≥ 70.
  7. For enrollment to the dose-finding cohort, subjects must have at least one (1) lesion ≥ 5 mm in diameter or two (2) or more lesions ≥ 3 mm in diameter. For the dose-expansion cohort, subjects must have by (RECIST) version 1.1.
  8. score of A6 or better.
  9. Adequate organ function.

Exclusion criteria

Exclusion Criteria:

  1. Recurrent HB who are candidates for complete surgical resection (e.g., isolated pulmonary relapse amendable to pulmonary metastasectomy).
  2. Pre-existing illness including heart failure, uncontrolled pulmonary disease not cancer-related, or psychiatric illness/social situation that would limit compliance with study requirements.
  3. Active, uncontrolled systemic bacterial, fungal, or viral infection. Subjects with (HIV), , or are eligible provided their infection is being treated and the viral load is controlled.
  4. Any known active (other than HB, HCN-NOS, or HCC).
  5. Pregnant or lactating women.
  6. Received the following within one (1) week of leukapheresis or within two (2) weeks of conditioning chemotherapy: cytotoxic chemotherapy, radiation, other anti-cancer therapies (including immunotherapeutic agents), or therapy. Systemic at doses greater than 5 mg/day of prednisone or equivalent doses of other corticosteroids within two (2) weeks prior to leukapheresis or conditioning chemotherapy or receipt of a T-cell engager (TCE) within two (2) months prior to leukapheresis or at any time as bridging therapy between leukapheresis and conditioning chemotherapy is exclusionary. (Note: Topical and inhaled corticosteroids in standard doses and physiological replacement doses of corticosteroids for adrenal insufficiency are allowed).
  7. Concurrently receiving other agents, biological, chemical, or radiation therapies, while participating in the study.
  8. for receipt of conditioning chemotherapeutic agents including Fludarabine and Cyclophosphamide.
  9. Active disease requiring systemic immunosuppressive therapy.
  10. Compromised circulation in the main portal vein, hepatic vein, or vena cava due to partial or complete obstruction which, in the opinion of the Investigator, would make the subject unsuitable for the study.
  11. History of organ transplant.
  12. HB, HCN-NOS, or HCC involving greater than 50% of the liver (volumetric).
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12 participants (estimated)

Study arms

  • Experimental
    ET140203 T Cells

    ET140203 Autologous T Cells

    Drug: ET140203 T Cells

Interventions

  • DrugET140203 T Cells

    Biological/Vaccine: ET140203 autologous T-cell product Autologous T cells transduced with lentivirus encoding an ET140203 expression construct

06

What researchers measure

Primary outcomes

  1. Incidence rates of adverse events (AEs) after infusion of ET140203 T cells

    Safety of ET140203 T cells as assessed by the number of adverse events (AEs) after infusion

    Time frame: 28 days

  2. Severity rates of adverse events (AEs) after infusion of ET140203 T cells

    Safety of ET140203 T cells as assessed by the severity of adverse events (AEs) after infusion.

    Time frame: 28 days

  3. Incidence rates of dose limiting toxicities (DLTs) after infusion of ET140203 T cells

    Tolerability of ET140203 T cells after infusions assessed by committee review of dose limiting toxicities (DLTs)

    Time frame: 28 days

  4. The recommended phase 2 dose (RP2D) regimen of ET140203 T cell therapy primarily based on DLT

    The RP2D will be determined by the study Dose Escalation Committee (DEC) and primarily based on DLTs.

    Time frame: Up to 2 years

Secondary outcomes

  1. Assess the efficacy of ET140203 T cells in pediatric subjects with relapsed/refractory HB, HCN-NOS, or HCC

    Response rate will be assessed by radiographic scans and assessed according to RECIST criteria.

    Time frame: Up to 2 years

  2. Determine the pharmacokinetics of ET140203 T cells after infusion.

    Assess the expansion and persistence of ET140203 T cells circulating in blood over time.

    Time frame: Up to 2 years

07

Study locations

4 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Dec 2027, 65 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2020
First posted
Nov 18, 2020
StartActual
Jul 19, 2022
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04634357
Lead sponsor
Eureka Therapeutics Inc.
Responsible party
Sponsor
First posted
Nov 18, 2020
Start date
Jul 19, 2022
Primary completion
Dec 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Jul 6, 2026

Study contacts

Teresa Klask, MBA
Contact
Teresa.Klask@eurekainc.com
510-722-8719 ext. 412
Pei Wang, PhD
Contact
Pei.Wang@eurekainc.com
510-654-7045
Pei Wang, PhD
study director · Eureka Therapeutics Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion